AZNAstraZenecaSigning up patients
Perioperative Durvalumab With Neoadjuvant ddMVAC in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
Urinary Bladder Neoplasms · Immune Checkpoint Inhibitors · Methotrexate · Vinblastine · Doxorubicin · Cisplatin · Gemcitabine
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 150 (planned)
- Started
- May 15, 2025
- Main results expected
- Aug 30, 2028
- Fully finished
- Aug 30, 2028
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
The safety of neoadjuvant durvalumab combined with ddMVAC prior to radical cystectomy (RC).
Measured over: Up to 6 months
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06960577 · record last updated 2026-10-08 · checked 2026-11-09 15:47 UTC